[1]马　壮　张万宏　刘关政　吴恒浩　张圣旭.STK40在脑胶质瘤中的表达及其临床意义的生信分析[J].中国临床神经外科杂志,2022,27(04):274-277.[doi:10.13798/j.issn.1009-153X.2022.04.010]
　MA Zhuang,ZHANG Wan-hong,LIU Guan-zheng,et al.Expression of STK40 in human glioma and and its clinical significance based on bioinformatics analysis[J].,2022,27(04):274-277.[doi:10.13798/j.issn.1009-153X.2022.04.010]
点击复制

STK40在脑胶质瘤中的表达及其临床意义的生信分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年04期
页码:
274-277
栏目:
论著
出版日期:
2022-04-30

文章信息/Info

Title:
Expression of STK40 in human glioma and and its clinical significance based on bioinformatics analysis
文章编号:
1009-153X（2022）04-0274-04
作者:
马　壮　张万宏　刘关政　吴恒浩　张圣旭
475000 河南开封，新乡医学院附属开封市中心医院神经外科（马　壮、张万宏、吴恒浩、张圣旭）；450003 郑州，河南省人民医院神经外科（刘关政）
Author(s):
MA Zhuang1;  ZHANG Wan-hong1;  LIU Guan-zheng2;  WU Heng-hao1;  ZHANG Sheng-xu1.
1. Department of Neurosurgery, Kaifeng Central Hospital Affiliated to Xinxiang Medical College, Kaifeng 475001, China; 2. Department of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou 450003, China
关键词:
脑胶质瘤; 丝氨酸/酸酸激酶 40; 基因表达; 生信分析
Keywords:
Glioma;  Serine/threonine protein kinase 40;  STK40;  Gene expression;  Bioinformatics methods
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2022.04.010
文献标志码:
A
摘要:
目的 探讨丝氨酸/酸酸蛋白激酶40（STK40）在脑胶质瘤中的表达及其临床意义。方法 计算机检索GEPIA数据库，运用生物信息学方法分析STK40在胶质瘤组织及正常脑组织中的表达差异；同时，检索CGGA数据库中693例脑胶质瘤的基因信息及临床资料，运用Kaplan-Meier生存曲线分析STK40表达水平与脑胶质瘤生存预后的关系；采用多因素Cox比例回归风险模型分析脑胶质瘤生存预后的影响因素。结果 GEPIA数据库分析显示，胶质母细胞瘤组织STK40表达水平较正常脑组织明显增高（P<0.05）。STK40表达水平与胶质瘤病理级别呈正相关，随胶质瘤病理级别增高，STK40表达水平明显增高（P<0.0001）。多因素Cox风险比例回归模型分析结果显示，STK40高表达是脑胶质瘤生存预后不良的独立危险因素（P<0.05）。Kaplan-Meier生存曲线分析显示，STK40高表达组中位总生存期较低表达组明显缩短（P<0.0001）；而且STK40高表达明显降低胶质瘤放/化疗的效果（P<0.0001）。Pearson相关性分析显示，ERK下游产物SRF与STK40呈明显正相关（r=0.45；P<0.0001），JNK下游产物ATF2与STK40表达水平呈明显负相关（r=-0.167；P<0.0001）。结论 胶质瘤STK40呈高表达，与病人生存预后不良有关，其作用机制可能与ERK/MAPK及JNK/MAPK信号通路有关。
Abstract:
Objective To investigate the expression of serine/threonine protein kinase (STK40) in gliomas and its clinical significance. Methods The GEPIA database was used to analyze the expression difference of STK40 in glioma tissues and normal brain tissues. Bioinformatics methods were used to analyze the gene information and clinical data of 693 patients with glioma obtained from the CGGA database. Kaplan-Meier survival curve was used to analyze the relationship between STK40 expression and survival time of patients with glioma. Multivariate Cox risk proportional regression model was used to analyze the risk factors of the survival prognosis of patients with glioma. Results The GEPIA database analysis showed that the STK40 expression level in the glioblastoma tissues was significantly higher than the normal brain tissues (P<0.05). The expression level of STK40 was positively correlated with the pathological grade of glioma, and the expression level of STK40 increased significantly with the increase of the pathological grade of glioma (P<0.0001). Multivariate Cox hazard proportional regression model analysis showed that high expression of STK40 was an independent risk factor for poor survival prognosis of glioma patients (P<0.05). Kaplan-Meier survival curve analysis showed that the median overall survival of the glioma patients with high expression of STK40 was significantly shorter than those with low expression of STK40 (P<0.0001); the high STK40 expression significantly reduced the curative effect of radiotherapy/chemotherapy on glioma (P<0.0001). Pearson correlation analysis showed that SRF, the downstream product of ERK, was positively correlated with STK40 (r=0.45; P<0.0001), and ATF2, the downstream product of JNK, was negatively correlated with the expression level of STK40 (r=-0.167; P<0.0001). Conclusions The high expression of STK40 in glioma is associated with poor survival prognosis of glioma patients, and its mechanism may be related to the ERK/MAPK and JNK/MAPK signaling pathways.

参考文献/References:

[1] Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016 [J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100.
[2] Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(5): 381-406.
[3] Tan AC, Ashley DM, Lopez GY, et al. Management ofglioblastoma: state of the art and future directions [J]. CA Cancer J Clin, 2020, 70(4): 299-312.
[4] Draaisma K, Chatzipli A, Taphoorn M, et al. Molecularevolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study [J]. J Clin Oncol, 2020, 38(1): 81-99.
[5] Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy [J]. CA Cancer J Clin, 2009, 59(2): 111-137.
[6] Letestu R, Levy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters [J]. Blood, 2010, 116(22): 4588-4590.
[7] Zhang W, Zhu Y, Zhou Y, et al. miRNA-31 increases radio-sensitivity through targeting STK40 in colorectal cancer cells [J]. Asia Pac J Clin Oncol, 2021. doi: 10.1111/ajco.13602. Online ahead of print.
[8] Asquith CRM, Temme L. STK19: a new target for NRAS-driven cancer [J]. Nat Rev Drug Discov, 2020, 19(9): 579.
[9] Maubant S, Tahtouh T, Brisson A, et al. LRP5 regulates the expression of STK40, a new potential target in triple-nega-tive breast cancers [J]. Oncotarget, 2018, 9: 22586-22604.
[10] Pan H, Liu Q, Zhang F, et al. High STK40 expression as an independent prognostic biomarker and correlated with immune infiltrates in low-grade gliomas [J]. Int J Gen Med, 2021, 14: 6389-6400.
[11] Huang T, Kim CK, Alvarez AA, et al. MST4 phosphoryla-tion of ATG4B regulates autophagic activity, tumorigeni-city, and radioresistance in glioblastoma [J]. Cancer Cell, 2017, 32(6): 840-855 e848.
[12] Palanichamy K, Kanji S, Gordon N, et al. NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability [J]. Clin Cancer Res, 2017, 23(9): 2325-2334.
[13] Li L, Sun L, Gao F, et al. Stk40 links the pluripotency factor Oct4 to the Erk/MAPK pathway and controls extraembryonicendoderm differentiation [J]. Proc Natl Acad Sci USA, 2010, 107(4): 1402-1407.
[14] Neuhofer P, Roake CM, Kim SJ, et al. Acinar cell clonalexpansion in pancreas homeostasis and carcinogenesis [J]. Nature, 2021, 597(7878): 715-719.
[15] Liu J, Chang F, Li F, et al. Palmitate promotes autophagy and apoptosis through ROS-dependent JNK and p38 MAPK [J]. Biochem Biophys Res Commun, 2015, 463(3): 262-267.

相似文献/References:

[1]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(04):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳　琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫　珊　徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
　YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(04):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(04):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民　褚会松　田　甜　王昆鹏　杨国军　杨立军　王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
　HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(04):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述　王　辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰　姚庆和　李晓辉　龙宇波　陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
　GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(04):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘　靖　吴立权　黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
　LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(04):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘　炎　杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明　胡新华　刘　永　陈　玖　刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
通讯作者：张万宏，E-mail：zhangwanhong2007@163.com
更新日期/Last Update: 1900-01-01